Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

NCT05140382 : A Modular Phase II, Open-label, Multicentre Study to Assess AZD4573 Efficacy and Safety as Monotherapy or in Combination With Anti-cancer Agents in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or Classical Hodgkin Lymphoma

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

TwoPhase Two

18-130Age 18-130

Blood<br/>CancersCancer LocationBlood
Cancers

Systemic therapy,Treatment | Blood / Myeloma / LymphomaHodgkin's Disease (Hodgkin's Lymphoma),Lymphoma,T-Cell Lymphoma

Trial Overview Read MoreRead more

This phase II study is assessing how safe and affective a new targeted therapy (AZD4573) is in people with either relapsed or refractory peripheral T-cell lymphoma or classical Hodgkins lymphoma.
 

This trial is treating patients with relapsed or refractory peripheral T-cell lymphoma and classical Hodgkins lymphoma.

This is a systemic therapy trial.

You may be able to join this trial if:

  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
  • You have had treatment, but your cancer has come back.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Modular Phase II, Open-label, Multicentre Study to Assess AZD4573 Efficacy and Safety as Monotherapy or in Combination With Anti-cancer Agents in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or Classical Hodgkin Lymphoma

Commercial Sponsor

AstraZeneca

Summary

This is a modular dose confirmation and expansion study. Module 1 of this study will evaluate how safe, tolerable and effective AZD4573 is as monotherapy. Eligible participants will be split into three cohorts depending on their diagnosis, and all participants will receive AZD4573 as monotherapy via intravenous infusion. If AZD4573 monotherapy is found to have promising anti-cancer effectiveness in Module 1, an AZD4573 monotherapy Phase II expansion may be added.

Recruiting Hospitals Read MoreRead more

PCCTU (Parkville Cancer Clinical Trials Unit) *
Parkville
Felicity McLeay
PCCTU.HaemB@petermac.org

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next